The approved therapy Yorvipath (palopegteriparatide) can improve kidney function in adults with hypoparathyroidism within months of initiating treatment, and these improvements are sustained for at least three years. That’s according to clinical trial data Yorvipath’s developer, Ascendis Pharma, shared this week at the annual meeting of…
People with chronic hypoparathyroidism who were prescribed the parathyroid hormone (PTH) replacement therapy Natpara had low health-related quality of life (HRQoL) and high symptom burden before starting treatment, according to a real-world study. The study compared patients who switched from conventional treatment to Natpara against those who stayed on…
A new study shows that Yorvipath (palopegteriparatide), a hormone replacement therapy, eliminates the need for conventional calcium and active vitamin D supplements in most adults with hypoparathyroidism. The therapy achieves this while keeping blood calcium levels stable and within the normal range. These findings come from a U.S.
Three months of once-weekly canvuparatide (MBX 2109) normalized blood calcium levels in most adults with chronic hypoparathyroidism, without the need for standard supplement therapy. That’s according to top-line data from a Phase 2 trial called Avail (NCT06465108), which enrolled 64 adults with chronic hypoparathyroidism who had been…
Treatment with Encaleret led to rapid normalization of both blood and urine calcium levels in a Phase 2 study involving people with chronic hypoparathyroidism. Within five days of treatment initiation, 80% of participants achieved normal calcium levels, whereas none had achieved such levels with conventional therapy at the…
People who develop chronic hypoparathyroidism following surgery are at high risk of kidney problems and infections, and they also tend to rack up hundreds of thousands of dollars in healthcare costs. That’s according to two studies led by scientists at Ascendis Pharma, both published in Advances in Therapy.
Biotech company Septerna is currently conducting preclinical tests to identify a lead experimental therapy for hypoparathyroidism, with the hope of starting clinical trials in 2026. “We are executing effectively across our portfolio, with each program nearing important milestones,” Jeffrey Finer, MD, PhD, CEO and co-founder of Septerna, said…
Technology used in real time may help surgeons identify a greater number of parathyroid glands during surgery — including in patients undergoing thyroidectomy, a procedure to remove part or all of the thyroid gland that is a common cause of hypoparathyroidism. That’s according to a new study that detailed…
Autotransplanting parathyroid glands to a muscle of the neck after surgery to remove the thyroid gland is tied to a higher risk of transient hypoparathyroidism, but progresses to permanent hypoparathyroidism less often, a study in China suggests. The risk of permanent hypoparathyroidism, that is, that which lasts more than…
The risk of fractures in the vertebrae, the bones in the spine, was 55% higher in people with chronic hypoparathyroidism than in the general population, a nationwide study in Sweden found. Conversely, the risk of femur (thighbone) fractures was 30% less common in the hypoparathyroidism group. Chronic hypoparathyroidism patients…
Get regular updates to your inbox.
